Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model

References

• Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391–398.
   PubMed Web of Science ®Google Scholar
• Lu QB, Zhang XA, Wo Y, et al. Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009–2011. PLoS One. 2012;7(12):e52073. https://doi.org/https://doi.org/10.1371/journal.pone.0052073.
   PubMed Web of Science ®Google Scholar
• Fang CY, Liu CC. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot and mouth disease. Expert Rev Vaccines. 2018;17(9):819–831.
   PubMed Web of Science ®Google Scholar
• Bian LL, Wang YP, Yao X, et al. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther. 2015;13(9):1061–1071.
   PubMed Web of Science ®Google Scholar
• Osterback R, Vuorinen T, Linna M, et al. Coxsackievirus A6 and hand, foot and mouth disease, Finland. Emerg Infect Dis. 2009;15(9):1485–1488.
   PubMed Web of Science ®Google Scholar
• Fonseca MC, Sarmiento L, Resik S, et al. Coxsackievirus A6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011–2013. Arch Virol. 2014;159(9):2451–2455.
   PubMed Web of Science ®Google Scholar
• Cisterna DM, Lema CL, Martinez LM, et al. Atypical hand, foot and mouth disease caused by coxsackievirus A6 in Argentina in 2015. Rev Argent Microbiol. 2019;51(2):140–143.
   Web of Science ®Google Scholar
• Lim CTK, Jiang L, Ma S, et al. Basic reproduction number of coxsackievirus type A6 and A16 and enterovirus 71: estimates from outbreaks of hand, foot and mouth disease in Singapore, a tropical city-state. Epidemiol Infect. 2016;144(5):1028–1034.
   PubMed Web of Science ®Google Scholar
• He SZ, Chen MY, Wu WH, et al. An emerging and expanding clade accounts for the persistent outbreak of coxsackievirus A6-associated hand, foot and mouth disease in China since 2013. Virology. 2018;518:328–334.
   Web of Science ®Google Scholar
• Meng XD, Tong YQ, Wei ZN, et al. Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. Sci Rep. 2020;10(1):20909. https://doi.org/https://doi.org/10.1038/s41598-020-77768-7.
   PubMed Web of Science ®Google Scholar
• Kimmis BD, Downing C, Tyring S. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis. 2018;102(5):353–356.
   PubMed Web of Science ®Google Scholar
• Xu LF, Zheng QB, Li SW, et al. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat Commun. 2017;8(1):505. https://doi.org/https://doi.org/10.1038/s41467-017-00477-9.
   PubMed Web of Science ®Google Scholar
• Mandary MB, Poh CL. Changes in the EV-A71 genome through recombination and spontaneous mutations: impact on virulence. Viruses. 2018;10(6):320. https://doi.org/https://doi.org/10.3390/v10060320.
   Web of Science ®Google Scholar
• Yang XH, Li YY, Zhang CB, et al. Clinical features and phylogenetic analysis of severe hand-foot-and-mouth disease caused by coxsackievirus A6. Infect Genet Evol. 2020;77:104054. https://doi.org/https://doi.org/10.1016/j.meegid.2019.104054.
   Web of Science ®Google Scholar
• Chen YJ, Chang SC, Tsao KC, et al. Comparative genomic analysis of coxsackievirus A6 strains of different clinical disease entities. PLoS One. 2012;7(12):e52432. https://doi.org/https://doi.org/10.1371/journal.pone.0052432.
   Web of Science ®Google Scholar
• Blomqvist S, Klemola P, Kaijalainen S, et al. Co-circulating of coxsackievirus A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48:49–54.
   PubMed Web of Science ®Google Scholar
• Gaunt E, Harvala H, Osterback R, et al. Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. J Gen Virol. 2015;96(5):1067–1079.
   Web of Science ®Google Scholar
• Zhu FC, Xu WB, Xia JL, et al. Efficacy, safety and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828.
   PubMed Web of Science ®Google Scholar
• Liu CC, Guo MS, Wu SR, et al. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58–66.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shen CY, Zhang C, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res. 2016;132:165–169.
   PubMed Web of Science ®Google Scholar
• Khong WX, Yan B, Yeo HM, et al. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012;86(4):2121–2131.
   PubMed Web of Science ®Google Scholar
• Xu Y, Ma SZ, Zhu LM, et al. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model. Antiviral Res. 2017;137:67–75.
   Web of Science ®Google Scholar
• Wang YF, Chou CT, Lei HY, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;78(15):7916–7924.
   Web of Science ®Google Scholar
• Wang W, Duo JY, Liu JN, et al. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect. 2011;13(10):862–870.
   Web of Science ®Google Scholar
• Yao PP, Qian L, Xia Y, et al. Enterovirus 71-induced neurological disorders in young gerbils, meriones unguiculatus: development and application of a neurological disease model. PLoS One. 2012;7(12):e51996. https://doi.org/https://doi.org/10.1371/journal.pone.0051996.
   Web of Science ®Google Scholar
• Lin YW, Yu SL, Shao HY, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8(2):e57591. https://doi.org/https://doi.org/10.1371/journal.pone.0057591.
   PubMed Web of Science ®Google Scholar
• Fujii K, Nagata N, Sato Y, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA. 2013;110(36):14753–14758.
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang YP, Gao R, et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012;86(22):11967–11976.
   PubMed Web of Science ®Google Scholar
• Shen CY, Liu QW, Zhou Y, et al. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34(41):5005–5012.
   PubMed Web of Science ®Google Scholar
• Li SX, Zhao H, Yang LS, et al. A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Res. 2017;144:247–255.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Dong ZP, Li J, et al. Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol. 2017;91(13):e00333–17.
   PubMed Web of Science ®Google Scholar
• Shen CY, Ku ZQ, Zhou Y, et al. Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. Vaccine. 2016;34(34):4025–4031.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Dong ZP, Wei QJ, et al. A neonatal murine model of coxsackievirus A6 infection for evaluation of antiviral and vaccine efficacy. J Virol. 2017;91(9):e02450–16.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Dong ZP, Wang Q, et al. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095–7104.
   PubMed Web of Science ®Google Scholar
• Yang LS, Mao QY, Li SX, et al. A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6. Antiviral Res. 2016;134:50–57.
   PubMed Web of Science ®Google Scholar
• Zhang W, Dai WL, Zhang C, et al. A virus-like particle-based tetravalent vaccine for hand, foot and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94. https://doi.org/https://doi.org/10.1038/s41426-018-0094-1.
   PubMed Web of Science ®Google Scholar
• Caine EA, Fuchs J, Das SC, et al. Efficacy of a trivalent hand, foot and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses. 2015;7(11):5919–5932.
   PubMed Web of Science ®Google Scholar
• Standardization Administration of China. Laboratory animal guideline for ethical review of animal welfare. 2018. Standardization Administration of China, Beijing, China.
   Google Scholar
• Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493–497.
   Google Scholar
• Khong WX, Foo DGW, Trasti SL, et al. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol. 2011;85(7):3067–3076.
   PubMed Web of Science ®Google Scholar
• Lin T-Y, Hsia S-H, Huang Y-C, et al. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis. 2003;36(3):269–274.
   PubMed Web of Science ®Google Scholar
• Shao P, Wu XX, Li HB, et al. Clinical significance of inflammatory cytokine and chemokine expression in hand, foot and mouth disease. Mol Med Rep. 2017;15(5):2859–2866.
   Web of Science ®Google Scholar
• Zhang WJ, Huang ZG, Huang MY, et al. Predicting severe enterovirus 71-infected hand, foot and mouth disease: cytokines and chemokines. Mediators Inflamm. 2020;2020:9273241. https://doi.org/https://doi.org/10.1155/2020/9273241.
   Web of Science ®Google Scholar
• Duan GC, Yang HY, Shi LB, et al. Serum inflammatory cytokine levels correlate with hand-foot-mouth disease severity: a nested serial case-control study. PLoS One. 2014;9(11):e112676. https://doi.org/https://doi.org/10.1371/journal.pone.0112676.
   Web of Science ®Google Scholar
• Zhang ZJ, Zhang XC, Carr MJ, et al. A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs. Emerg Microbes Infect. 2019;8(1):1445–1455.
   PubMed Web of Science ®Google Scholar
• Jin WP, Lu J, Zhang XY, et al. Efficacy of coxsackievirus A5 vaccine candidates in an actively immunized mouse model. J Virol. 2021;95:e01743–20.
   PubMed Web of Science ®Google Scholar
• Yu CK, Chen CC, Chen CL, et al. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci. 2000;7(6):523–528.
   PubMed Web of Science ®Google Scholar
• Wang KT, Lin SJ, Wang HC, et al. Establishment of an animal challenge model as a potency assay for an inactivated enterovirus type 71 vaccine. Biologicals. 2016;44(4):183–190.
   PubMed Web of Science ®Google Scholar
• Domingo E, Sabo D, Taniguchi T, et al. Nucleotide sequence heterogeneity of an RNA phage population. Cell. 1978;13(4):735–744.
   PubMed Web of Science ®Google Scholar
• Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151–178.
   PubMed Web of Science ®Google Scholar
• Caine EA, Moncla LH, Ronderos MD, et al. A single mutation in the VP1 of enterovirus 71 is responsible for increased virulence and neurotropism in adult interferon-deficient mice. J Virol. 2016;90(19):8592–8604.
   PubMed Web of Science ®Google Scholar
• Lancaster KZ, Pfeiffer JK. Limited trafficking of a neurotropic virus through inefficient retrograde axonal transport and the type I interferon response. PLoS Pathog. 2010;6(3):e1000791. https://doi.org/https://doi.org/10.1371/journal.ppat.1000791.
   Web of Science ®Google Scholar
• Ren R, Racaniello VR. Poliovirus spreads from muscle to the central nervous system by neutral pathways. J Infect Dis. 1992;166(4):747–752.
   PubMed Web of Science ®Google Scholar